Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics announced a collaboration on November 11, 2025 to co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' new DNBSEQ-T1+ sequencing platform.

The integrated sample-to-report workflow targets precision oncology research by combining MSK-validated assays and AI analytics with DNBSEQ-T1+ sequencing, which delivers Q40-level accuracy, throughput of 500 million–2 billion reads per flow cell, a 24-hour PE150 run time, and capacity up to 60 tumor-normal tissue pairs or 16 tumor-normal liquid biopsy pairs per flow cell.

Joint evaluation showed high concordance in variant calls and allele frequencies, plus lower background noise and reduced turnaround time versus equivalent systems. The offering is positioned for clinical labs, cancer centers, and drug developers globally.

SOPHiA GENETICS (NASDAQ: SOPH) and Element Biosciences announced a partnership on November 11, 2025 to integrate SOPHiA DDM™ AI analytics with Element's AVITI and AVITI24 sequencing systems. The collaboration aims to deliver an end-to-end NGS workflow that combines sequencing speed and multiomic capability with AI-driven variant analysis to help clinical researchers generate actionable insights more quickly.

AVITI and AVITI24 users will gain access to SOPHiA DDM applications in oncology and rare disease, enabling local genomic research with expanded analytical tools.

SOPHiA GENETICS (Nasdaq: SOPH) reported Q3 2025 results: revenue $19.5M (+23% YoY), net IFRS loss $20.0M (+9% YoY) and adjusted EBITDA loss $10.2M (+8% YoY). Adjusted gross margin was 73.1% (adjusted basis). Excluding elevated Swiss social charges, adjusted EBITDA loss would have been $8.8M, a 13% YoY improvement.

Management raised 2025 revenue guidance to $75–$77M (growth 15–18%) and expects adjusted EBITDA loss of $39–$41M. Q3 operational highlights: 99,000 analyses (+9% YoY), 31 new customers, average contract value of new signings +180% YoY, and U.S. revenue growth of 30% YoY.

SOPHiA GENETICS (Nasdaq: SOPH) will release its third quarter 2025 financial results before U.S. markets open on Tuesday, November 4, 2025.

The company will host a conference call and webcast to discuss the results and business outlook on Nov 4, 2025 at 8:00 a.m. EDT / 2:00 p.m. CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations website and a replay will be available on the site after the call.

SOPHiA GENETICS (Nasdaq: SOPH) and A.D.A.M. Innovations announced a strategic partnership on October 16, 2025 to bring AI-powered liquid biopsy genomic testing and a companion diagnostic (CDx) to Japan.

The collaboration will launch the MSK-ACCESS® liquid biopsy application powered by SOPHiA DDM™, analyze samples in-house at A.D.A.M.'s Tokyo lab, and pursue development of a local CDx to support personalized oncology, faster turnaround times, lower patient costs, and pharmaceutical trial support. A.D.A.M. has completed over 2.8 million genomic tests and has operated in Japan for over 20 years.

SOPHiA GENETICS (NASDAQ: SOPH) announced on October 16, 2025 the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates dynamic virtual patient replicas using clinical, imaging, biological, and genomic data. The tool simulates treatment responses, disease trajectories, and survival outcomes in real time, generates synthetic data for research, and continuously improves as new data are added. Initial rollout is on the SOPHiA DDM™ Platform for lung cancer, with additional cancer types planned in coming months.

SOPHiA GENETICS (Nasdaq: SOPH) has expanded its collaboration with AstraZeneca to enhance breast and prostate cancer detection through advanced AI technology. The partnership focuses on developing an optimized next-generation sequencing (NGS) solution that employs AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.

The companies have already developed a prototype demonstrating improved sensitivity in mutation detection. SOPHiA GENETICS will implement a Privileged Access Program for selected clinical laboratories, with broader commercial availability expected in 2026. The program includes a multi-center real-world evidence study to validate the technology's effectiveness in clinical settings.

SOPHiA GENETICS (Nasdaq: SOPH) has announced a strategic partnership with Jessa Ziekenhuis, one of Belgium's largest healthcare institutions, to enhance genomic testing and oncology research. The collaboration involves implementing SOPHiA DDM™ platform across Jessa's pathology operations, integrating six specialized applications for various cancer analyses.

The partnership aims to achieve significant operational improvements, including 30-50% reduction in hands-on time, up to 25% cost reduction, and faster testing turnaround times. Notably, the collaboration includes a unique arrangement where Jessa Ziekenhuis will share a NovaSeq sequencer with AZ Delta through the Bridge Consortium, optimizing sequencing capacity and knowledge sharing across Belgian healthcare institutions.

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2025 financial results with revenue of $18.3 million, up 16% year-over-year. The company achieved an adjusted gross margin of 74.4%, improving 120 basis points from the previous year. Despite growth, IFRS net loss increased 48% to $22.4 million.

Key operational highlights include performing 95,000 analyses on SOPHiA DDM™, signing 35 new core genomics customers, and securing a major AI breast cancer partnership with AstraZeneca. The company maintains its 2025 guidance of $72-76 million in revenue and expects to approach adjusted EBITDA breakeven by end of 2026.